US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist
  • 1.280
  • +0.040+3.23%
Close Jul 12 16:00 ET
  • 1.320
  • +0.040+3.13%
Post 19:54 ET
327.12MMarket Cap-1763P/E (TTM)

Adaptimmune Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Adaptimmune Therapeutics Earnings Date

Currency: USD

Period

Q1 FY2024 Earnings

May 15, 2024

Revenue(YoY)

5.68M

-88.07%
EPS(YoY)

-0.18

-2996.68%
Analyst Rating

Buy

Jul 4, 2024

Adaptimmune Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 8 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 8.875M--
--2024/Q2-- / 37.858M--
May 15, 20242024/Q15.678M / 20.480M--
Mar 6, 20242023/Q4231.000K / 25.960M--
Nov 8, 20232023/Q37.319M / 15.140M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 8.875M--
--2024/Q2-- / 37.858M--
May 15, 20242024/Q15.678M / 20.480M--
Mar 6, 20242023/Q4231.000K / 25.960M--
Nov 8, 20232023/Q37.319M / 15.140M--

Unlock Free Earnings Estimates

Adaptimmune Therapeutics Earnings Reports

  • Adaptimmune Therapeutics | 10-Q: Quarterly report

    May 15 22:23 ET

  • Adaptimmune Therapeutics | 10-K: Annual report

    Mar 6 07:18 ET

  • Adaptimmune Therapeutics: Q3 2023 Earnings Report

    Nov 8, 2023 16:05 ET

  • Adaptimmune Therapeutics | 10-Q: Q2 2023 Earnings Report

    Aug 9, 2023 16:06 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jul 4, 2024

    Buy

    • Buy

      57.14%

    • Hold

      28.57%

    • Sell

      14.29%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    %Chg
    Concept CAR-T Therapy
    CAR-T Therapy
    Intraday+0.74%